Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Maxim Soloviev"'
Autor:
Phillip C C Liu, Holly Koblish, Liangxing Wu, Kevin Bowman, Sharon Diamond, Darlise DiMatteo, Yue Zhang, Michael Hansbury, Mark Rupar, Xiaoming Wen, Paul Collier, Patricia Feldman, Ronald Klabe, Krista A Burke, Maxim Soloviev, Christine Gardiner, Xin He, Alla Volgina, Maryanne Covington, Bruce Ruggeri, Richard Wynn, Timothy C Burn, Peggy Scherle, Swamy Yeleswaram, Wenqing Yao, Reid Huber, Gregory Hollis
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231877 (2020)
Alterations in fibroblast growth factor receptor (FGFR) genes have been identified as potential driver oncogenes. Pharmacological targeting of FGFRs may therefore provide therapeutic benefit to selected cancer patients, and proof-of-concept has been
Externí odkaz:
https://doaj.org/article/f6f5510fe9c645f98e36ce8e4425a929
Publikováno v:
Journal of Mining Institute.
Obtaining and production of metals from natural raw materials causes a large amount of liquid, solid, and gaseous wastes of various hazard classes that have a negative impact on the environment. In the production of titanium dioxide from ilmenite con
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bbcf100cd3199695d65a7a2d3df77e
https://doi.org/10.1158/2159-8290.22540981.v1
https://doi.org/10.1158/2159-8290.22540981.v1
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::170fab3f863c9be0aad6f9e19f25879b
https://doi.org/10.1158/2159-8290.22540984.v1
https://doi.org/10.1158/2159-8290.22540984.v1
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Blocking the activity of the programmed cell death protein 1 (PD-1) inhibitory receptor with therapeutic antibodies against either the ligand (PD-L1) or PD-1 itself has proven to be an effective treatment modality for multiple cancers. Contrasting wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6486db56a65286928bd5907136280e12
https://doi.org/10.1158/2159-8290.c.6549529
https://doi.org/10.1158/2159-8290.c.6549529
Autor:
Gregory Hollis, Wenqing Yao, Reid Huber, Peggy Scherle, Jeff Jackson, Swamy Yeleswaram, Cindy Marando, Ryan Geschwindt, Pramod Thekkat, Yue Zhang, Christina Stevens, Luping Lin, Darlise DiMatteo, Mark Rupar, Gengjie Yang, Chrysi Kanellopoulou, Stephen Rubin, Kevin O'Hayer, Maxim Soloviev, Sharon Diamond, Jingwei Li, Yan-ou Yang, Maryanne Covington, Elham Behshad, Kanishk Kapilashrami, Nina Zolotarjova, Alla Volgina, Hao Liu, Susan Spitz, Jonathan Rios-Doria, Richard Wynn, Phillip C.C. Liu, Liang-Chuan S. Wang, Liangxing Wu, Holly K. Koblish
Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5739e2f7911a281a155113d1f5d765bd
https://doi.org/10.1158/2159-8290.22540987
https://doi.org/10.1158/2159-8290.22540987
Autor:
Liang-Chuan S. Wang, Rinse Klooster, Ashwini Kulkarni, Amaya Garcia de Vinuesa, Maxim Soloviev, Linda JA Hendriks, Lu Huo, Michael Weber, Arpita Mondal, Yonghong Zhao, Shane Harvey, Xin He, Hong Chang, April Horsey, Alla Volgina, Yue Zhang, Veethika Pandey, Yan-Ou Yang, Jonathan Rios-Doria, Evgeniy Eruslanov, Daniel J. Powell, Steven M. Albelda, John de Kruif, Horacio Nastri, Cecile Geuijen, Patrick A. Mayes
Publikováno v:
Cancer Research. 83:2936-2936
Transforming growth factor-β (TGFβ) signaling is common in many solid tumors and is initiated by binding of the high affinity canonical ligands TGFβ1, 2, οr 3 to TGFβR2, which forms a heteromeric receptor complex with TGFβR1 (Derynck et al, Nat
Autor:
Qian Wang, Sybil O'Connor, Alan Roberts, Brian W. Metcalf, Leslie Hall, Maxim Soloviev, Michael Hansbury, Greg Hollis, Xin He, Matthew C. Stubbs, Niu Shin, Wenqing Yao, Kamna Katiyar, Phillip C.C. Liu, Kathy Wang, Sharon Diamond, Brent Douty, Gengjie Yang, Dana Shuey, Maryanne B. Covington, Paul Collier, Mingming Gao, Patricia Feldman, Peggy Scherle, Timothy Burn, Andrew P. Combs, Yun-Long Li, Lynn Leffet, Robert C. Newton, Paul Waeltz, Holly Koblish, Jin Lu, Swamy Yeleswaram, Yanlong Li, Reid Huber, Robert Collins, Eddy W. Yue
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 374:211-222
The clinical use of first-generation phosphoinositide 3-kinase (PI3K)δ inhibitors in B-cell malignancies is hampered by hepatotoxicity, requiring dose reduction, treatment interruption, and/or discontinuation of therapy. In addition, potential molec
Autor:
Holly K. Koblish, Liangxing Wu, Liang-Chuan S. Wang, Phillip C.C. Liu, Richard Wynn, Jonathan Rios-Doria, Susan Spitz, Hao Liu, Alla Volgina, Nina Zolotarjova, Kanishk Kapilashrami, Elham Behshad, Maryanne Covington, Yan-ou Yang, Jingwei Li, Sharon Diamond, Maxim Soloviev, Kevin O'Hayer, Stephen Rubin, Chrysi Kanellopoulou, Gengjie Yang, Mark Rupar, Darlise DiMatteo, Luping Lin, Christina Stevens, Yue Zhang, Pramod Thekkat, Ryan Geschwindt, Cindy Marando, Swamy Yeleswaram, Jeff Jackson, Peggy Scherle, Reid Huber, Wenqing Yao, Gregory Hollis
Publikováno v:
Cancer discovery. 12(6)
Blocking the activity of the programmed cell death protein 1 (PD-1) inhibitory receptor with therapeutic antibodies against either the ligand (PD-L1) or PD-1 itself has proven to be an effective treatment modality for multiple cancers. Contrasting wi
Autor:
Niu, Shin, Matthew, Stubbs, Holly, Koblish, Eddy W, Yue, Maxim, Soloviev, Brent, Douty, Kathy He, Wang, Qian, Wang, Mingming, Gao, Patricia, Feldman, Gengjie, Yang, Leslie, Hall, Michael, Hansbury, Sybil, O'Connor, Lynn, Leffet, Robert, Collins, Kamna, Katiyar, Xin, He, Paul, Waeltz, Paul, Collier, Jin, Lu, Yun-Long, Li, Yanlong, Li, Phillip C C, Liu, Timothy, Burn, Maryanne, Covington, Sharon, Diamond, Dana, Shuey, Alan, Roberts, Swamy, Yeleswaram, Greg, Hollis, Brian, Metcalf, Wenqing, Yao, Reid, Huber, Andrew, Combs, Robert, Newton, Peggy, Scherle
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 374(1)
The clinical use of first-generation phosphoinositide 3-kinase (PI3K)